Context Therapeutics Inc.
5 clinical trials · Sponsor
◉ Watch Context Therapeutics Inc.
| Record | Firm | Date |
|---|---|---|
| A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers (NCT07545122) | Context Therapeutics Inc. | 2026-09-01 |
| CT-95 in Advanced Cancers Associated With Mesothelin Expression (NCT06756035) | Context Therapeutics Inc. | 2025-03-31 |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors (NCT06515613) | Context Therapeutics Inc. | 2024-07-10 |
| A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer (NCT06938711) | Context Therapeutics Inc. | 2023-06-01 |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer (NCT05618613) | Context Therapeutics Inc. | 2022-12-02 |
Track Context Therapeutics Inc. automatically
Every clearance here is in the API, with alerts when new ones post.